Stock HLVX HILLEVAX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

HilleVax, Inc. Stock

Equities

HLVX

US43157M1027

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
12.79 USD +6.41% Intraday chart for HilleVax, Inc. +3.98% -20.31%
Apr. 05 Hillevax Insider Sold Shares Worth $264,467, According to a Recent SEC Filing MT
Mar. 21 Stifel Adjusts HilleVax Price Target to $34 From $30, Maintains Buy Rating MT

Financials (USD)

Sales 2024 * - Sales 2025 * - Capitalization 616M
Net income 2024 * -160M Net income 2025 * -198M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-4.13 x
P/E ratio 2025 *
-3.65 x
Employees 90
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.09%
More Fundamentals * Assessed data

Chart HilleVax, Inc.

Dynamic Chart

Latest news about HilleVax, Inc.

Hillevax Insider Sold Shares Worth $264,467, According to a Recent SEC Filing MT
Stifel Adjusts HilleVax Price Target to $34 From $30, Maintains Buy Rating MT
HilleVax Insider Sold Shares Worth $985,536,428, According to a Recent SEC Filing MT
HilleVax Proposes $500 Million Offering of Equity, Debt Securities in Shelf Registration MT
HilleVax Q4 Net Loss Widens; Shares Extend Decline After Hours MT
HilleVax, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
HilleVax, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
HilleVax Names New Chief Operating Officer MT
HilleVax Taps Sean McLoughlin as Chief Operating Officer DJ
HilleVax, Inc. Announces Executive Changes CI
Kanghua Biological Products Licenses Norovirus Vaccine to HilleVax MT
Certain Options of HilleVax, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2023. CI
Certain Restricted Stock Units of HilleVax, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2023. CI
Certain Common Stock of HilleVax, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2023. CI
HilleVax, Inc.(NasdaqGS:HLVX) dropped from NASDAQ Biotechnology Index CI
More news

Analyst Recommendations on HilleVax, Inc.

Hillevax Insider Sold Shares Worth $264,467, According to a Recent SEC Filing MT
Stifel Adjusts HilleVax Price Target to $34 From $30, Maintains Buy Rating MT
HilleVax Insider Sold Shares Worth $985,536,428, According to a Recent SEC Filing MT
HilleVax Proposes $500 Million Offering of Equity, Debt Securities in Shelf Registration MT
HC Wainwright Initiates HilleVax With Buy Rating MT
More recommendations

Press releases HilleVax, Inc.

HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress GL
HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference GL
HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer GL
HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China GL
HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China AQ
More press releases

Quotes and Performance

1 day+6.41%
1 week+3.98%
Current month-23.09%
1 month-23.09%
3 months-16.68%
6 months+16.86%
Current year-20.31%
More quotes

Highs and lows

1 week
11.79
Extreme 11.79
13.20
1 month
11.73
Extreme 11.73
16.66
Current year
11.73
Extreme 11.73
20.22
1 year
9.94
Extreme 9.94
20.22
3 years
7.90
Extreme 7.9
24.42
5 years
7.90
Extreme 7.9
24.42
10 years
7.90
Extreme 7.9
24.42
More quotes

Managers and Directors - HilleVax, Inc.

Managers TitleAgeSince
Robert Hershberg CEO
 Chief Executive Officer 61 20-02-29
Shane Maltbie DFI
 Director of Finance/CFO 42 21-11-30
Anju Chatterji CTO
 Chief Tech/Sci/R&D Officer - 21-12-31
Members of the board TitleAgeSince
Robert Hershberg CEO
 Chief Executive Officer 61 20-02-29
Jeryl Hilleman BRD
 Director/Board Member 66 21-03-31
Shelley Chu BRD
 Director/Board Member 54 21-07-31
More insiders

ETFs positioned on HilleVax, Inc.

Name Weight AuM 1st Jan change Investor Rating
ADAPTIVE RH TACTICAL OUTLOOK ETF - USD ETF Adaptive RH Tactical Outlook ETF - USD
0.00% 9 M€ +6.26% -
More ETFs positioned on HilleVax, Inc.

Quotes

Date Price Change Volume
24-04-26 12.79 +6.41% 369,590
24-04-25 12.02 -4.45% 52,392
24-04-24 12.58 -1.80% 49,066
24-04-23 12.81 -1.31% 162,714
24-04-22 12.98 +5.53% 88,390

Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT

More quotes

Company Profile

HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The Company's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-216 includes six common norovirus genotypes, GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
Sector
Biotechnology & Medical Research
Calendar
2024-06-04 - Q1 2024 Earnings Release (Projected)
Related indices
Russell 2000
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.79 USD
Average target price
29 USD
Spread / Average Target
+126.74%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
HILLEVAX, INC. Stock HilleVax, Inc.
-20.31% 616M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. HLVX Stock